Developing treatments for neurodegenerative diseases
Alpha Cognition is a clinical stage, biopharmaceutical company. They’re dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS).
Alzheimer’s disease is a chronic neurodegenerative disease that is the cause of 60–80% of cases of dementia. The company’s therapy for Alzheimer’s Dementia has the potential to be the first significant improvement in over a decade.
ALPHA-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. Furthermore, it is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. It benefits from minimal gastrointestinal side effects and novel routes of administration. ALPHA-1062’s active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia and in a nasal spray formulation to treat traumatic brain injury.
ALPHA-0602 (Progranulin) is expressed in several cell types in the central nervous system and in peripheral tissues, regulates cell survival and certain inflammatory processes, as well as plays a major role in regulating lysosomal function and microglial responses to disease. Its use for the treatment of neurodegenerative diseases has been patented by the Company and granted an Orphan Drug Designation.
For more information on Alpha Cognition Inc. (TSX.V: ACOG) please click the request investor info button.